Although treatment-resistant schizophrenia (TRS) was described 50 years ago 1 and has a
gold standard treatment with clozapine based on well-defined criteria, 2 there is still a matter …

Introduction Antipsychotics (AP) induce weight gain. However, reviews and meta-analyses
generally are restricted to second generation antipsychotics (SGA) and do not stratify for …

Background As the burden of treatment-resistant schizophrenia (TRS) on patients and
society is high it is important to identify predictors of response to medications in TRS. The …

Objective Clozapine is considered as the standard treatment for this subgroup, but the
evidence is not unequivocal. There are several potential alternatives being used because of …

Introduction: Schizophrenia is a debilitating condition with three main symptom domains:
positive, negative, and cognitive. Approximately one-third of persons with schizophrenia will …

Introduction Our objective was to conduct a systematic review and meta-analysis of adverse
effects on sleep in patients with schizophrenia receiving antipsychotic treatment. Methods A …

BackgroundImprovements are greatest in the earlier weeks of antipsychotic treatment of
patients with non-resistant schizophrenia. AimsTo address the early time-line for …

It is one of the major psychiatric dogmas that the efficacy of all antipsychotic drugs is same.
This statement originated from old, narrative reviews on first-generation antipsychotics, but …

Despite consistent recommendations for antipsychotic monotherapy, antipsychotic
polypharmacy (the use of two or more antipsychotic agents) and the administration of …

Background Levomepromazine is an'older'typical antipsychotic medication licensed for use
in schizophrenia but sparingly prescribed in the United Kingdom. Objectives To determine …